ABRAXANE Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma

10-Nov-2009 - USA

Abraxis BioScience, Inc. announced that the Office of Orphan Products Development of the food and Drug Administration (FDA) has granted Orphan Drug Designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

“As we advance our pivotal clinical trials of ABRAXANE in pancreatic cancer and melanoma, we look forward to the potential of bringing a new treatment option to patients with these difficult to treat cancers,” said Lonnie Moulder, President and Chief Executive Officer.

Abraxis continues to study the potential of ABRAXANE in a variety of tumor types.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances